Friday, April 14, 2017

Bee Products Used to Treat Cancer, Rheumatoid Arthritis

Honey bee products used as medicine

Guardian, 4/13/2017

Bee products such as honey, venom have been used in folk medicine for thousands of years for treating wounds, ulcers, inflammation, infections, pain, allergies and cancer.

Bee venom therapy, the therapeutic application of bee venom have been used in traditional medicine to treat diseases, such as arthritis, rheumatism, pain, cancerous tumors and kin diseases. Bee venom contains a variety of peptides including melittin, apamin, adolapin, the mast – cell-degranulating peptide, enzymes (phospolipase A2), biologically active amines (that is histamine and epinephrine) and nonpeptide components with a variety of pharmaceutical properties.

Cancer treatment

Bee venom has been widely used in the treatment of tumours. Several cancer cells, including renal, lung, liver, prostate, mammary gland as well as leukemia cells can be targets of bee venom peptides such as melittin and phospholipase A2.

In recent study scientists reported that bee venom can induce apoptosis in cancer cells (in human leukemic U937cells) the key regulators in bee venom induced apoptosis are Bcl-2 and caspase-3 through down regulation of the ERK and Akt signal pathway. Melittin, a water-soluble toxic peptide derived from bee venom of Apis mellifera was reported to have inhibitory effects on hepatocellular carcinoma. Melittin inhibits tumor cell metastasis by reducing motility and migration via the suppression of Rac-1 dependent pathway, suggesting that melittin is a potent therapeutic agent for hepatocellular carcinoma. Melittin prevents liver cancer cells metastasis through inhibition of the Rac-1-dependent pathway.

Treatment for rheumatoid arthritis

Bee venom induces apoptosis in rheumatoid synovial cells through a decrease in BCL2 expression and an increase in BAX and caspase-3 expression. Bee venom induces apoptosis through caspase-3 activation in synovial fibroblasts of patients with rheumatoid arthritis...

No comments: